This is an observational, retrospective, multicenter study based on the use of demographic, clinical and biological data from deceased patients admitted between 2018 and 2022 to critical care with a principal or associated diagnosis of joint prosthesis infection. Data from this study will be combined with that from the OASIS study (APHP241174/ ID-RCB: 2024-A01769-38) concerning osteoarticular sepsis on prosthetic material in critical care of living patients. The aim of this study is to improve our knowledge of the profile, care trajectories and outcomes of patients hospitalized in critical care in the context of osteoarticular material sepsis. The results of the study could help identify at-risk populations and improve management strategies for patients with osteoarticular sepsis.
Study Type
OBSERVATIONAL
Enrollment
150
All deceased patients admitted to intensive care during the study period and satisfying the eligibility criteria.
Hôpital Lariboisière
Paris, France, France
RECRUITINGEpidemiological description of deceased patients
Demographic data, medical history, history of Periprosthetic Joint Infection (timing, diagnosis, surgery, antibiotics), data in intensive care unit (leng of stay, organ failure, drugs and mechanical support, biological data) and outcome (time of death within 2 years after admission to Intensive Care Units).
Time frame: 2 years
Composite endpoint reflecting poor clinical outcome
* Mortality, measured in critical care, at 30 days, 1 year and 2 years. * Therapeutic failure at 2 years, defined as mechanical or septic failure. * Functional failure at 2 years, defined as failure to resume walking and usual activities, to return home, or to regain autonomy.
Time frame: 2 years
Mortality at 2 years
Time frame: 2 years
Epidemiological description based on the number (n) and proportion (%) of bacterial strains found in samples collected during the operation.
Special focus on: Gram-positive bacteria (Staphylococcus, Streptococcus, Enterococcus), Gram-negative bacteria (Enterobacteriacea, Pseudmononas), slow-growing bacteria (Cutibacterium, Corynenbacteria), yeasts; resistance mechanisms (meticillin, rifampicin, quinolone, glycopeptide, ESBL, carbapenem).
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.